The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors
Abstract We determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma (NDMM) patients in the current era of myeloma therapy. A total of 393 MM patients were included in the final analysis. The median followup was 83 months (range: 3.9 to 212 mon...
Main Authors: | Barry Paul, Yue Zhao, Gavin Loitsch, Daniel Feinberg, Parker Mathews, Ian Barak, Megan Dupuis, Zhiguo Li, Lindsay Rein, Endi Wang, Yubin Kang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-08-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3265 |
Similar Items
-
Isatuximab, pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma in real clinical practice
by: Vadim V. Ptushkin, et al.
Published: (2024-12-01) -
The effect of marital status on the survival of patients with multiple myeloma
by: Lina Tang, et al.
Published: (2022-12-01) -
EPIDEMIOLOGY OF MULTIPLE MYELOMA ACCORDING TO THE КIROV REGION POPULATION REGISTERS
by: A. S. Luchinin, et al.
Published: (2017-10-01) -
Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review
by: Yanjie Zhang, et al.
Published: (2024-12-01) -
Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
by: Zhenhai Li, et al.
Published: (2020-08-01)